Bausch & Lomb (BLCO) Other financing activities (2023 - 2026)
Bausch & Lomb's (BLCO) quarterly Other financing activities came in at $2.0 million in Q1 2026, up 200.0% quarter-over-quarter from -$2.0 million in Q4 2023.
Powered by 
Analysis
Bausch & Lomb (BLCO) Other financing activities (2023 - 2026) Analysis & Trends
Bausch & Lomb (BLCO) has reported Other financing activities for 2 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (up 200.0% YoY), and the FY2024 full-year result was -$1.0 million, up 50.0% from the prior year.
- Other financing activities climbed to $2.0 million in Q1 2026 per BLCO's latest filing, from -$2.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $2.0 million in Q1 2026 and bottomed at -$2.0 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn |
| 10 | Bausch & Lomb | 6.28 Bn | 5.90 Bn | 867.00 Mn |